Acute pancreatitis
Acute pancreatitis (AP) is a relatively common acute abdomen, and its incidence ranks third to fifth among acute abdomens. More than 80% of patients have mild symptoms, namely acute edematous pancreatitis, which can be cured by non-surgical means and is basically a medical disease. About 10% of patients have severe pancreatitis, namely acute hemorrhagic necrotizing pancreatitis. The inflammation of the pancreas is no longer reversible or self-limiting, and often requires surgical treatment. It should be regarded as a surgical disease. Due to the in-depth understanding of acute pancreatitis, the diagnostic technology and treatment methods have been greatly developed, and it has become a very interesting issue for surgeons. At the same time, the mortality rate remains high, reaching 30% to 60%, and various serious complications are prone to occur, which is a severe challenge for doctors.
-
Site of disease:
pancreas
-
Infectious :
Not contagious
-
Frequent population:
All people, any occurrence during pregnancy...
-
Related symptoms:
Pancreatic abdominal pain
Sudden right upper abdominal colic
Nausea and vomiting
Acute abdomen
Upper abdominal tenderness
Related Drugs
Ulinastatin Injection
Indication: 1. Acute pancreatitis; 2. Chronic recurrent pancreatitis; 3. Rescue and auxiliary medication for acute circulatory failure.
Manufacturer:
Techpool BIO-PHARMA Co., Ltd.
Ulinastatin for injection
Indication: 1Acute pancreatitis; 2Chronic recurrent pancreatitis; 3Rescue and auxiliary medication for acute circulatory failure.
Manufacturer:
Techpool BIO-PHARMA Co., Ltd.
Aprotinin
Indication: Inhibits trypsin, chymotrypsin and fibrinolytic enzymes. Used for fibrinolytic phenomena, acute pancreatitis and pancreatic necrosis.
Aprotinin
Indication: Inhibits trypsin, chymotrypsin and fibrinolytic enzymes. Used for fibrinolytic phenomena, acute pancreatitis and pancreatic necrosis.
Manufacturer:
Jiuquan Dadeli Pharmaceutical Co., Ltd.
Octreotide Acetate Injection
Indication: This product is suitable for: 1. Emergency treatment of esophageal-gastric varicose bleeding caused by liver cirrhosis, combined with special treatments (such as endoscopic sclerotherapy); 2. Prevention of complications after pancreatic surgery; 3. Relieve symptoms and signs related to gastrointestinal endocrine tumors. There is sufficient evidence to show that this product is effective for the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors; glucagon tumors. The efficacy of this product for the following tumors is about 50% (so far, the number of cases treated with this product is limited): gastrinoma/Zollinger-Ellison syndrome, insulinoma, growth hormone releasing factor tumor; 4. After surgery, radiotherapy or dopamine receptor
Manufacturer:
Hainan Zhonghe Pharmaceutical Co., Ltd.